NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease; A prospective randomized trial

"Patients with diabetes mellitus represent a high risk group with exaggerated potential for cardiovascular events such as heart failure. It should not be assumed those events are inevitable, however. Studies suggest we are now able to detect risk for such cardiac events in patients with diabetes using NT-proBNP, and intervene to reduce the likelihood for development of disease. The PONTIAC II Trial will provide pivotal guidance regarding the role of such biomarker-intensified therapy."

James Louis Januzzi, M.D.